~~<i id='374541C362'><strike id='374541C362'><tt id='374541C362'><pre id='374541C362'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：Wikipedia 2025-09-29 05:00:17 Page View：4

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Pediatricians' group reaffirms support for gender
Next article： Medical leaders decry Supreme Court decision on affirmative action

leisure time

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

'Cuddling' is just what the doctor ordered for a 200

InthisphotoprovidedbytheAlaskaSeaLifeCenter,WildlifeResponseAnimalCareSpecialistsHalleyWerner,left,a

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

The nurse manager staffing crisis is hurting patients

JaeC.Hong/APThoughtheCovid-19pandemicbroughtheightenedattentiontonursesoverall,auniquenursingrolehas